Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
sulfasymazine
- Development stage
- Discontinued
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Sulfasymazine is a long-acting sulfonamide antibiotic. It acts as a competitive inhibitor of the enzyme dihydropteroate synthase, which is responsible for the conversion of para-aminobenzoic acid (PABA) into dihydropteroate, a precursor of folic acid. By blocking this pathway, sulfasymazine inhibits bacterial DNA synthesis and growth. It was primarily utilized for the treatment of urinary tract infections and other systemic bacterial infections due to its high solubility in urine and prolonged duration of action compared to earlier sulfonamides.
- Brand names
- Symasul
- Other names
- SulfasymazinumN1-(4,6-diethyl-s-triazin-2-yl)sulfanilamide
02
Targets
DHPS (Dihydropteroate synthase)
Beyond the preview
Go deeper on sulfasymazine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on sulfasymazine.